Triptodur® (triptorelin extended-release suspension)

Triptodur (triptorelin ER) is covered only for pediatric patients ≥2 years with central precocious puberty and for compendial off‑label use in gender‑dysphoric/gender‑incongruent individuals or those undergoing gender reassignment; other indications are not covered. Approval requires prescription by or consultation with an endocrinologist or a transgender‑care specialist, documentation of diagnosis and age (for CPP), a treatment plan with intent to give 22.5 mg IM every 24 weeks, and is authorized for up to 12 months.

"Triptodur is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP)."

Sign up to see full coverage criteria, indications, and limitations.